Devyser Diagnostics AB
Devyser Diagnostics AB (publ) engages in the development, manufacture, and sale of diagnostic kits and solutions for DNA testing within hereditary diseases, oncology, and post-transplantation monitoring in Sweden, rest of Europe, the Middle East, Africa, North and South America, and Asia. The company offers products in the areas of post-transplantation; thalassemia; breast, colorectal, and ovaria… Read more
Devyser Diagnostics AB (DVYSR) - Total Liabilities
Latest total liabilities as of September 2025: Skr119.00 Million SEK
Based on the latest financial reports, Devyser Diagnostics AB (DVYSR) has total liabilities worth Skr119.00 Million SEK as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Devyser Diagnostics AB - Total Liabilities Trend (2018–2024)
This chart illustrates how Devyser Diagnostics AB's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Devyser Diagnostics AB Competitors by Total Liabilities
The table below lists competitors of Devyser Diagnostics AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Spheria Emerging Companies Ltd
AU:SEC
|
Australia | AU$7.13 Million |
|
Fu Chun Shin Machinery Manufacture Co Ltd
TWO:6603
|
Taiwan | NT$5.72 Billion |
|
Generalplus Technology Inc
TW:4952
|
Taiwan | NT$719.26 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥216.30 Million |
|
402490
KQ:402490
|
Korea | ₩68.56 Billion |
|
Lavipharm S.A
AT:LAVI
|
Greece | €72.52 Million |
|
RideNow Group, Inc.
NASDAQ:RDNW
|
USA | $386.70 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down Devyser Diagnostics AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.78 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.35 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Devyser Diagnostics AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Devyser Diagnostics AB (2018–2024)
The table below shows the annual total liabilities of Devyser Diagnostics AB from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr124.80 Million | -0.16% |
| 2023-12-31 | Skr125.00 Million | +80.66% |
| 2022-12-31 | Skr69.19 Million | +72.19% |
| 2021-12-31 | Skr40.18 Million | -7.80% |
| 2020-12-31 | Skr43.58 Million | +18.78% |
| 2019-12-31 | Skr36.69 Million | +101.02% |
| 2018-12-31 | Skr18.25 Million | -- |